BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8827870)

  • 21. Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33.
    Vercauteren S; Zapf R; Sutherland H
    Cytotherapy; 2007; 9(2):194-204. PubMed ID: 17453971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
    Xie W; Wang X; Du W; Liu W; Qin X; Huang S
    Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haemopoietic progenitor cell differentiation: flow cytometric assessment in bone marrow and thymus.
    Tjønnfjord GE; Steen R; Veiby OP; Mørkrid L; Egeland T
    Br J Haematol; 1995 Dec; 91(4):1006-16. PubMed ID: 8547112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of granulocyte colony-stimulating factor receptor increases with differentiation in myeloid cells by a newly-devised quantitative flow-cytometric assay.
    Shinjo K; Takeshita A; Ohnishi K; Ohno R
    Br J Haematol; 1995 Dec; 91(4):783-94. PubMed ID: 8547119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells.
    Shinjo K; Takeshita A; Ohnishi K; Ohno R
    Leuk Lymphoma; 1997 Mar; 25(1-2):37-46. PubMed ID: 9130612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
    Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
    Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
    Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow.
    Ashman LK; Cambareri AC; To LB; Levinsky RJ; Juttner CA
    Blood; 1991 Jul; 78(1):30-7. PubMed ID: 1712644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow.
    Kinniburgh D; Russell NH
    Bone Marrow Transplant; 1993 Nov; 12(5):489-94. PubMed ID: 7507766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts.
    Sonneveld P; Wiemer E
    Leukemia; 1997 Jul; 11(7):1160-5. PubMed ID: 9205006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells.
    Gaipa G; Coustan-Smith E; Todisco E; Maglia O; Biondi A; Campana D
    Haematologica; 2002 Apr; 87(4):347-56. PubMed ID: 11940478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).
    Jiang Y; Xu P; Yao D; Chen X; Dai H
    Med Sci Monit; 2017 Apr; 23():1725-1732. PubMed ID: 28391288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemias resembling acute promyelocytic leukemia, microgranular variant.
    Nagendra S; Meyerson H; Skallerud G; Rosenthal N
    Am J Clin Pathol; 2002 Apr; 117(4):651-7. PubMed ID: 11939742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression].
    Matsui H; Takeshita A; Naito K; Onishi K; Ono R
    Rinsho Ketsueki; 2002 May; 43(5):309-15. PubMed ID: 12096475
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
    J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
    Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
    Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
    Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
    Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.